Aligos (ALGS) in Focus: Stock Moves 5.6% Higher

In this article:

Aligos Therapeutics, Inc. ALGS was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continue the recent uptrend for the company — as the stock is now up 15.5% in the past one-month time frame.

The company has seen no estimates revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Aligos currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Aligos Therapeutics, Inc. Price

Aligos Therapeutics, Inc. Price
Aligos Therapeutics, Inc. Price

Aligos Therapeutics, Inc. price | Aligos Therapeutics, Inc. Quote

 

A better-ranked stock in the Medical sector is Alimera Sciences, Inc. ALIM, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alimera Sciences, Inc. (ALIM) : Free Stock Analysis Report
 
Aligos Therapeutics, Inc. (ALGS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement